34results about How to "Delay disease progression" patented technology

The invention relates to the field of chronic disease early warning, and discloses a chronic disease early warning intervention system based on artificial intelligence, and the system comprises a data collection module which is used for collecting multi-modal data, and the multi-modal data comprises gene detection data, proteomics data, microbiomics data, environment data and social economic data; the pre-processing module is used for pre-processing the multi-modal data to obtain basic data, and the pre-processing comprises noise removal, abnormal value and missing value processing and targeted data cleaning and feature extraction operation on the data of different modals; and a conversion fusion module. Through cooperative operation of all the modules, a complete and automatic chronic disease early warning intervention process is formed, an organic whole is formed from data acquisition, risk assessment and intervention measure formulation and implementation, and the chronic disease risk whole process management and control are achieved, so that the chronic disease prevention and treatment efficiency and effect are improved.

The invention relates to the technical field of immunodetection, in particular to a hybridoma cell strain secreting an anti-threonine phosphorylated tau protein monoclonal antibody. The hybridoma cell strain for secreting the p-tau181 monoclonal antibody is preserved in the China Center for Type Culture Collection, and the preservation numbers of the hybridoma cell strain and the hybridoma cell strain are respectively CCTCC NO: C2024272 and CCTCC NO: C2024273. The hybridoma cell strain can be used for preparing a monoclonal antibody capable of specifically recognizing p-tau181 and aggregate thereof, and the problem that a targeted p-tau181 antibody is lacked at present is solved. The invention has the advantages that the two monoclonal antibodies can be further applied subsequently to prepare a high-specificity and high-sensitivity p-tau181 detection kit, the passive immunological treatment of specific targeting p-tau181 is developed, the disease progress is slowed down, and the blank of the current immunological treatment of targeting p-tau181 is filled up.

The invention relates to the technical field of prediction and evaluation of lung cancer samples, and discloses a prediction and evaluation method of a lung cancer sample, which comprises the following steps: collecting clinical information of a lung cancer patient, acquiring biological data of the lung cancer sample, sorting medical image data, extracting key genes, proteins or pathway characteristics from the biological data, important features related to the lung cancer are screened by using a statistical method or a machine learning algorithm, a proper machine learning or deep learning model is selected according to data characteristics and a prediction target, and the interpretability, stability and calculation complexity of the model are considered. According to the method, tumors with high-risk characteristics, such as tumors with high invasiveness and high metastasis potential, can be found and intervened in time through prediction and evaluation of lung cancer samples, so that the disease progress is delayed, the treatment effect is improved, the treatment effect and disease change can be monitored through regular prediction and evaluation of the lung cancer samples in the treatment process, and the treatment effect is improved. The treatment scheme is adjusted in time, and the maximization of the treatment effect is ensured.

The invention provides application of urolithin A in Alzheimer's disease, belongs to the technical field of medicinal chemistry and treatment of mental diseases, and aims to solve the problem of social anxiety caused by the Alzheimer's disease. According to the application disclosed by the invention, the mitochondrial autophagy effect of urolithin A is utilized, A beta is eliminated, a key brain region loop aBLA-vCA1 is repaired, and the anxiety symptom of a patient suffering from the Alzheimer's disease is relieved. According to the present invention, with the application of the urolithin A in the treatment of Alzheimer's disease, through the mitochondrial autophagy function of the urolithin A, the targeted removal of A beta and the repair of the damaged basal outer side amygdala nucleus and hippocampus loop are achieved so as to effectively relieve the anxiety symptom of the patient and provide the new strategy for the AD treatment.

The invention discloses a heart valvular disease digital management system, which relates to the technical field of medical data management, and is characterized in that a data acquisition module comprises an automatic acquisition unit and a multi-channel input unit; the storage management module comprises a data storage unit and a data management unit; the monitoring and early warning module comprises a data analysis unit and a health early warning unit; the data visualization module comprises a chart display unit, a dynamic interaction unit and a report generation unit; the health assistant module comprises a personalized management unit, a follow-up visit management unit, a health activity evaluation unit, an intelligent reasoning unit and a family member unit. The system has an early risk perception and hospital-family linkage valvular heart disease full-process digital health management mode, can improve the active health management ability of patients, controls disease risk factors, effectively restrains the risk of cardiovascular diseases, and improves the overall quality and efficiency of medical services.

The invention discloses an overexpression vector of LAMP2B and application thereof, which can effectively delay the disease progress of DMD, and comprises: (a) an AAV vector which is an adeno-associated virus vector and has high muscle tissue targeting and low liver tropism; (b) a CMV (cytomegalovirus) promoter, wherein the CMV promoter is a cytomegalovirus promoter; (c) a coding sequence of an hLAMP2B gene, namely a coding sequence of a human LAMP2B gene, and the coding sequence of the hLAMP2B gene is operably linked to the CMV promoter; wherein the vector is configured to overexpress LAMP2B protein in muscular tissue, and the vector is self-complementary AAV, namely scAAV, the concept is ingenious, the novel AAV vector with high muscle transformation efficiency is utilized to deliver a complete LAMP2B gene (LAMP2B is a gene related to autophagy regulation) into muscle cells of all organs of a mouse (AAV-hLAMP2B for short), and the autophagy regulation function of the mouse is improved. The muscle tissue function of the mouse DMD disease model is comprehensively assisted to recover, and the disease progress of the DMD is delayed.

The present invention discloses a method for using a biotherapy for novel coronavirus (SARS-CoV-2) infection, wherein the protein is DEFA1 (human defensin α1, or human neutrophil peptide, HNP-1). The reagents include but are not limited to: 1) DEFA1 recombinant protein; 2) a vector containing a DEFA1 encoding gene; 3) a reagent for detecting RNA expression of DEFA1. The experimental research results of the present invention provide a new biotherapy method for novel coronavirus infection, and provide a new drug target for treating respiratory tract lesions caused by novel coronavirus infection.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The invention relates to the field of medical diagnosis, in particular to application of a group of plasma exosome biomarkers in preparation of a Parkinson's disease transformation prediction and ultra-early diagnosis kit, and the plasma exosome biomarkers are composed of NFL and CXCL12. A series of exosome biomarker screening is carried out on baseline plasma exosomes of iRBD patients in a longitudinal follow-up queue (5 years) of the iRBD patients, and it is found that the possibility that the iRBD patients with the plasma exosomes NFL and CXCL12 develop into the Parkinson's disease in the future is remarkably improved; and NFL and CXCL12 are combined to carry out transformation prediction and ultra-early diagnosis on the Parkinson's disease of an iRBD patient.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for preventing and treating chronic obstructive pulmonary diseases and / or emphysema. The traditional Chinese medicine composition is prepared from 5-30 parts of herba houttuyniae, 5-30 parts of honeysuckle flowers, 5-20 parts of radix paeoniae rubra, 3-15 parts of folium artemisiae argyi and 3-15 parts of herba menthae. The invention finds that the composition can obviously improve FVC, FEV0.3 and PEF of rats, obviously reduce the level of inflammatory factors IL-17, increase the content of serum alpha1-AT of the rats after molding, prevent progressive destruction of alveolar walls, reduce the content of serum HA and PCIII of the rats and delay the disease progress of emphysema on smoked and LPS composite replication COPD models and elastinase-induced emphysema model rats. Therefore, the traditional Chinese medicine composition disclosed by the invention has a good effect of treating the chronic obstructive pulmonary disease.

The invention discloses a method for researching the influence of S100A9 on AQP4 and an influence mechanism of the S100A9, and relates to the technical field of biomedicine. Comprising the following steps: cell culture; the method comprises the following steps: inoculating U251 astroglioma cells or SD (Sprague Dawley) rat primary astroglioma cells into a culture dish, after the cells are completely adhered to the wall, replacing a culture medium containing S100A9 proteins with different concentrations, and continuously culturing for 12 hours; the cell activity is detected through CCK8; and adding a CCK8 reagent into the culture dish, incubating for a period of time, and detecting the activity of each group of cells. The invention provides a systematized and detailed research method, and the influence of the S100A9 on the AQP4 can be clarified; through the experimental steps of cell culture, CCK8 detection, Western Blot, RT-qPCR and the like, the change of the S100A9 on the expression and positioning of the AQP4 under different concentrations can be comprehensively known.

The invention discloses a functional composition and complete food for kidneys of dogs and cats and a preparation method of the functional composition and the complete food, and relates to the technical field of animal feed. The functional composition comprises a plant extract, prebiotics and probiotics. The plant extract consists of an astragalus extract, a rhodiola rosea extract, a centella asiatica extract, a gynostemma pentaphylla extract and a poria cocos extract. The prebiotics are composed of fucoidan, synanthrin and lactulose. The probiotics are prepared from streptococcus thermophilus, lactobacillus acidophilus and bifidobacterium longum. According to the functional composition and the complete food for the kidney of the dog and the cat and the preparation method of the functional composition and the complete food, plant extracts, prebiotics and probiotics are selected to be matched, and the functional composition and the complete food have the anti-oxidation, anti-inflammatory and anti-fibrosis effects on the kidney of the dog and the cat. The complete food containing the functional composition for the kidneys of the dogs and the cats is applied to pet food, so that the kidney injury of the dogs and the cats can be prevented or the disease progress of chronic kidney diseases of the dogs and the cats can be delayed.

The invention discloses a construction method and application of an overexpression growth inhibition and DNA damage induction gene 45 gamma adenovirus. The construction method comprises the following steps: 1) constructing a recombinant shuttle plasmid containing a GADD45 gamma gene; 2) co-transforming the recombinant shuttle plasmid containing the GADD45 gamma gene and an adenovirus skeleton plasmid into escherichia coli cells, and generating a recombinant GADD45 gamma adenovirus plasmid through homologous recombination; and 3) transfecting the recombinant GADD45 gamma adenovirus plasmid into a 293 cell, packaging the recombinant GADD45 gamma adenovirus plasmid by the 293 cell to obtain adenovirus particles with infection activity, and amplifying and purifying the recombinant GADD45 gamma adenovirus in the 293 cell to obtain the recombinant GADD45 gamma adenovirus. The overexpressed GADD45 gamma adenovirus slows down the disease progress of CIA mice, avoids joint destruction of the CIA mice, provides a new method and a new theory for clinical prevention and diagnosis of RA, and provides a new target for treatment of rheumatoid arthritis and autoimmune diseases.

The invention belongs to the technical field of Chinese medicine preparation, and specifically is a preparation method and application of a Chinese medicine preparation for treating hypertension complicating pregnancy. The method comprises the following steps: washing and drying Chinese medicinal materials in a prescribed amount, crushing them respectively, and mixing them uniformly to obtain a mixed powder A; soaking the remaining components in water according to the prescribed amount, decocting, filtering, and concentrating to obtain a Chinese medicine extract with a relative density; putting the obtained extract into a vacuum dryer for fluidized drying, and crushing them to obtain a mixed powder B after combined operation; and mixing the mixed powder A and the mixed powder B uniformly and sealing them for storage to obtain a finished product, so as to give full play to the efficacy of each medicine and avoid the loss of efficacy, so as to achieve a high release rate of the effective ingredients of the medicine, and significantly improve the stability and solubility of the medicine, thereby improving the therapeutic effect and cure rate of the medicine.

This invention provides a method for controlling potato verticillium wilt using ABT rooting powder, comprising: fully dissolving ABT rooting powder in alcohol, diluting with distilled water, and setting aside; removing 2-week-old Désirée and Zhongshu 19 test-tube seedlings, cutting off the roots, soaking the base of the potato stems in ABT rooting powder, planting them in a hydroponic box, observing the growth of the potato roots, and selecting a suitable concentration of ABT rooting powder for later use; planting Désirée and Zhongshu 19 test-tube seedlings, and when the plants have grown to 4-6 true leaves, preparing a suspension of non-alfalfa Verticillium Vn011 spores and irrigating the base of the potato stems; irrigating the base of the potato stems with ABT rooting powder 3 days after inoculation with the pathogen; calculating the disease severity and disease index 20, 30, and 40 days after inoculation with the pathogen; harvesting potatoes 50 days after inoculation with the pathogen, measuring yield, and observing and statistically analyzing the growth of the potato roots. This invention utilizes ABT rooting powder to promote the rapid growth of potato roots and plants, thereby achieving the purpose of preventing and controlling potato verticillium wilt.

The present invention provides the use of Circ-0000818 in preparing a biomarker for diagnosing liver fibrosis. The present invention also provides the use of a reagent for detecting Circ-0000818 in preparing a kit for diagnosing liver fibrosis. The present invention also provides the use of circ-0000818 in preparing a drug for treating liver fibrosis. Through research, it was found that the expression of circ-0000818 in liver tissue of patients with liver fibrosis was significantly decreased, and increasing the expression of circ-0000818 in hepatic stellate cells can alleviate the progression of liver fibrosis. Circ_0000818 adenovirus was used to treat mice with liver fibrosis induced by CCL4, and the reporter gene found that circ-0000818 can inhibit the expression of miR-484, thereby regulating the expression of autophagy-related genes and liver fibrosis-related genes in stellate cells.

The present invention relates to the technical field of traditional Chinese medicine, and provides an application of a traditional Chinese medicine composition in the preparation of treating postmenopausal osteoporosis. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 25-35 parts of Glossy Privet Fruit, 10-20 parts of Morinda officinalis How, 10-20 parts of Drynaria fortunei (Kunze) J. Sm., and 5-15 parts of Alisma orientale (Sam.) Juz. Among them, Glossy Privet Fruit is the monarch drug, with a mild nature, being good at nourishing the liver and kidney, and replenishing yin and generating essence; Morinda officinalis How and Drynaria fortunei (Kunze) J. Sm. together serve as the ministerial drugs, and Alisma orientale (Sam.) Juz. serves as the assistant and guiding drug. The whole formula can achieve the effects of tonifying both yin and yang, tonifying without stagnation, and dispelling pathogenic factors and strengthening healthy qi.

The invention belongs to the technical field of biological medicines, and particularly relates to an ovary-targeting drug carrier as well as a preparation method and application thereof. Specifically, the invention provides a targeted ovarian drug carrier ZIF-8-GH-ZP3, so as to realize targeted treatment of POI and targeted ovarian release of growth hormone to improve the treatment effect and reduce the adverse reaction of the growth hormone. According to the design of the drug carrier, a zeolite imidazole skeleton (ZIF-8) and a zona pellucida antibody (ZP3Ab) are adopted, growth hormones can be released in a targeted mode according to follicles developed at different levels in an ovary, targeted therapy of primary ovarian insufficiency is finally achieved based on the dual functions of targeting and promoting development of dominant follicles of the growth hormones, and the drug carrier has good practical application value.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention discloses an application of a benzo-aza derivative in preparation of a medicine for preventing or treating atherosclerosis, the benzo-aza derivative is a compound with a chemical structure as shown in a formula I, or a pharmaceutically acceptable salt, a precursor or a metabolite of the compound, and in the formula I, X is halogen or H. The traditional Chinese medicine composition has the technical effects that the plaque stabilizing effect is obvious, the plaque composition is improved, the necrosis core area in the plaque is reduced, the total plaque load can be effectively reduced, the lesion progress is delayed / reversed, the dependence on lipid reduction is avoided, the treatment blank is filled, a brand new plaque stabilizing treatment strategy is provided, and the clinical problem of residual cardiovascular risks is expected to be solved. The safety is good, the organ specificity is high, and the whole body toxicity is low. The invention provides a new treatment normal form, new use of old medicines and large clinical transformation potential, and can be used as a supplement and enhancement of a basic therapy (such as statin lipid reduction) to form a combined treatment scheme of lipid reduction and spot stabilization, thereby realizing multi-channel cooperative control of atherosclerosis.

This invention provides a traditional Chinese medicine composition for treating androgenetic alopecia, formulated from the following raw materials in parts by weight: 1.5-3 parts of processed Polygonum multiflorum, 1.5-3 parts of Drynaria fortunei, 0.5-1.5 parts of Glycyrrhiza uralensis, 2.5-3 parts of raw Platycladus orientalis leaves, 2.5-3 parts of Salvia miltiorrhiza, 1.5-3 parts of Angelica sinensis, and 1-2 parts of Ligusticum chuanxiong. The above-mentioned traditional Chinese medicine composition is obtained by decocting and concentrating the herbs after soaking them in cold water for 20-30 minutes. This invention uses traditional Chinese medicinal materials that promote blood circulation, nourish blood and essence, and have anti-inflammatory and anti-allergic effects as raw materials. It has multiple effects, including improving blood circulation and nourishing hair follicles, thus curing hair loss from the root cause. The synergistic effect of the above-mentioned herbs not only nourishes hair but also prevents hair loss and moisturizes the skin.

This invention discloses the use of oligomycin A in the preparation of a drug for competitively inhibiting EphB3 to reverse lorlatinib resistance, belonging to the field of biomedical technology. This invention experimentally discovered that EphB3 is a key factor mediating lorlatinib resistance in lung cancer, and that existing oligomycin A can effectively reverse EphB3-mediated resistance by competitively binding to EphB3. Based on this, this invention protects the use of oligomycin A in the preparation of a drug for reversing lorlatinib resistance in tumors (especially ALK-positive non-small cell lung cancer). Simultaneously, this invention also protects a therapeutically effective pharmaceutical composition comprising oligomycin A and lorlatinib, and a non-therapeutic method for reversing cellular resistance to lorlatinib in vitro. This invention provides a novel and effective solution for overcoming lorlatinib resistance in clinical practice.

The application relates to an application of a traditional Chinese medicine composition in a drug for chronic obstructive pulmonary disease, characterized in that the traditional Chinese medicine composition comprises the following components in parts: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Amygdalus 1-100 parts, Notopterygium 1-100 parts, Zingiber officinale 1-100 parts, Pogostemonis 1-100 parts, Perilla 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-160 parts, Atractylodes macrocephala 1-120 parts, Gypsum fibrosum 1-100 parts, Fructus Crataegi 1-100 parts, Fructus Junci 1-100 parts, Fructus Hordei 1-100 parts, Lumbricus 1-100 parts, Radix et Rhizoma Veratri 1-100 parts, Herba Eupatorii Fortunei 1-100 parts, Semen Lepidii 1-100 parts and Semen Platycladi 1-100 parts.

The invention discloses a cognitive impairment assessment method based on an OCT imaging technology, and belongs to the technical field of cognitive impairment prediction. According to the cognitive impairment prediction method based on the OCT imaging technology, the result prediction accuracy is high, the phenomena of missed diagnosis and indefinite diagnosis are effectively reduced / avoided, and the method has important practical value for early discovery of cognitive impairment; the method has the advantages that lumbar puncture does not need to be carried out on a person to be detected, the method is non-invasive, less pain is brought to the person to be detected, the safety is high, popularization of cognitive impairment screening is facilitated, high-risk people with cognitive impairment can be judged, early intervention on the patient with cognitive impairment is further realized, and the onset progress of cognitive impairment is delayed; the method is simple and easy to operate, and many examinations and measurements can be realized by setting parameters for instruments and equipment.

The invention relates to the technical field of medicinal plant cultivation, in particular to an LED light formula for synergistically improving resistance, yield and quality of anoectochilus formosanus and application of the LED light formula. The transplanted anoectochilus formosanus is treated by using LED blue light, red light and far-red light groups, the antioxidant enzyme activity and lignin content of plants of the treatment group are remarkably improved compared with those of a control group, the stem rot disease progress is delayed, and the morbidity and disease index are obviously reduced; the LED light formula provided by the invention has a stable yield effect in the production of anoectochilus formosanus, and is beneficial to increasing the yield of dry anoectochilus formosanus; the LED light formula provided by the invention is beneficial to accumulation of effective active ingredient polysaccharide in anoectochilus formosanus, and can promote deep development of anoectochilus formosanus polysaccharide products. Synergistic improvement of anoectochilus formosanus disease resistance, biomass accumulation and polysaccharide content can be achieved.

The present invention discloses a Parkinson's disease diagnostic marker combination and its application, and relates to the field of biomedical technology. The Parkinson's disease diagnostic marker combination includes α-synuclein and CD81 on the neuronal extracellular vesicle membrane in serum. The present invention also provides the use of a reagent for detecting the content of the Parkinson's disease diagnostic marker combination in serum in the preparation of a diagnostic product for Parkinson's disease. The present invention has found that the ratio of α-synuclein and CD81 on the neuronal extracellular vesicle membrane can achieve an effective diagnosis of Parkinson's disease, and the AUC value in the receiver operating characteristic curve can reach 0.94. The present invention provides a new strategy for neuronal extracellular vesicle membrane protein markers for the accurate diagnosis of Parkinson's disease, showing significant advantages in improving diagnostic accuracy and efficiency.

The application discloses macrophage membrane-coated methacrylated hyaluronic acid hydrogel microspheres and application, relates to the technical field of drug synthesis, and technical solution points are that a kind of macrophage membrane-coated methacrylated hyaluronic acid hydrogel microspheres EMM@HMs can efficiently neutralize key proinflammatory factors, the proinflammatory factor includes TNF-alpha and IL-1 beta, to relieve joint inflammation.It is good in the curative effect and biocompatibility in OA model, especially its effect in the regulation of macrophage polarization, inhibition of chondrocyte hypertrophy and neutralization of proinflammatory factors.EMM@HMs can not only significantly reduce inflammation by targeting the key link in the pathogenesis of OA, but also has the potential to delay disease progression, providing a new strategy with a breakthrough significance for the treatment of OA.

This invention discloses a CH@SHP099-NPs composite hydrogel, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the technical challenge of achieving long-term, safe, and precise metabolic intervention with SHP2, this invention constructs a hydrogel system composed of chondroitin sulfate and hyaluronic acid. This system can retain SHP099-loaded nanoparticles within the joint cavity, forming a long-acting intrasynovial drug library, thereby continuously inhibiting the SHP2-AMPK signaling axis. The CH@SHP099-NPs composite hydrogel prepared in this invention can effectively reprogram the metabolic state of macrophages, reduce glycolysis flux, restore synovial immune metabolic homeostasis, and significantly improve synovial inflammation, chondrocyte activity, and cartilage structural integrity in vivo. This invention proposes a mechanism-guided local delivery metabolic intervention strategy, which is expected to provide a new interventional approach for the treatment of osteoarthritis.

The invention provides a method for preventing and treating potato verticillium wilt by using ABT rooting powder, which comprises the following steps: fully dissolving the ABT rooting powder in alcohol, and diluting with distilled water for later use; the method comprises the following steps: taking out test-tube plantlets of Desiree and Zhongshu 19 at the seedling age of 2 weeks, cutting off root systems, soaking potato stem bases in ABT rooting powder, planting the potato stem bases in a water culture box, observing the growth condition of the potato root systems, and screening the ABT rooting powder with proper concentration for later use; planting Desiree and Zhongshu 19 test-tube plantlets, preparing a non-alfalfa verticillium Vn011 spore suspension when the plant grows to 4-6 true leaves, and irrigating the non-alfalfa verticillium Vn011 spore suspension to the base part of a potato stem; 3 days after the pathogenic bacteria are inoculated, ABT rooting powder is poured to the base parts of potato stems; after inoculating the pathogenic bacteria for 20 days, 30 days and 40 days, counting the disease grade, and calculating the disease index; harvesting the potatoes 50 days after inoculating the pathogenic bacteria, measuring the yield, and observing and counting the root growth condition of the potatoes. The ABT rooting powder is utilized to promote rapid growth of potato root systems and plants, and the purpose of preventing and treating potato verticillium wilt is achieved.